Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemisinin-piperaquine combination therapies for childhood malaria in Papua New Guinea
ACTRN12605000550606Phase 4Recruiting
- Sponsor
- The University of Western Australia
- Start
- Apr 2005
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dihydroartemisinin, piperaquine, artesunate, chloroquine, sulfadoxine and 1 more in malaria, Falciparum malaria (PF) and vivax malaria (4 arms), sponsored by The University of Western Australia. Primary endpoint: 28-day cure rate. Started Apr 2005; status: recruiting.
02
Drugs
dihydroartemisininpiperaquineartesunatechloroquinesulfadoxine
03
Conditions
malariaFalciparum malaria (PF)vivax malaria
Beyond the preview
Go deeper on ACTRN12605000550606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000550606.